exelixis inc (EXEL:NASDAQ GS)
Earnings & Estimates Summary - EXELIXIS INC (EXEL)
2013 revenues at Exelixis, Inc. totaled $31.3M USD, while annual losses equaled $1.32 per share.
Quarterly Earnings & Estimates - EXELIXIS INC (EXEL)
Exelixis, Inc.'s Quarterly Earnings
Exelixis, Inc. reported 1st quarter 2014 losses of $0.39 per share on 05/3/2014.
Annual Earnings & Estimates - EXELIXIS INC (EXEL)
Exelixis, Inc.'s Annual Earnings
Exelixis, Inc. reported annual 2013 losses of $1.32 per share on 02/22/2014.
Quarterly Revenues - EXELIXIS INC (EXEL)
Exelixis, Inc.'s Quarterly Revenues
Exelixis, Inc. had 1st quarter 2014 revenues of $4.9M USD. This missed the $6.1M USD consensus estimate of the 9 analysts following the company. This was -49.3% below the prior year's 1st quarter results.
Annual Revenues - EXELIXIS INC (EXEL)
Exelixis, Inc.'s Annual Revenues
Exelixis, Inc. had revenues for the full year 2013 of $31.3M USD. This was -34.0% below the prior year's results.
|ARIAD Pharmaceuticals Inc||$5.76 USD||-0.36|
|Array BioPharma Inc||$4.00 USD||-0.24|
|CrystalGenomics Inc||17,850 KRW||+850.00|
|CTI BioPharma Corp||$2.59 USD||-0.06|
|Evotec AG||€3.96 EUR||-0.122|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|